rotonin receptor inhibitor—cypotolamine on endogenous opiate peptide concentration in spinal cord. Cypotolamine injection denotes the beginning of cypotolamine administration. Cypotolamine 100 ng group (○, n = 8): the animal was given 100 ng cypotolamine into the spinal cord; Cypotolamine 50 ng group (×, n = 8): the animal was given 50 ng cypotolamine into the spinal cord; Control group (▲, n = 8): the animal was not given cypotolamine into the spinal cord. The data are expressed as mean ± standard error mean (SEM). *P < 0.05, **P < 0.01 and ***P < 0.001 are used for the comparison of the change of L-enkephaline, β-endorphin or dynorphin A1-13 concentration from cypotolamine 100 ng group or cypotolamine 50 ng group and control group.

in 5 min (P < 0.001), 2.9 ± 1.3 pg/mg in 10 min (P < 0.001) and 4.2 ± 1.4 pg/mg in 20 min (P < 0.01); Administration of 50 ng cypotolamine into the spinal cord decreased DynA1-13 concentration in the spinal cord from 6.5 ± 1.8 pg/mg (tissue weight) to 3.1 ± 1.0 pg/mg in 5 min (P < 0.001), 4.8 ± 1.3 pg/mg in 10 min (P < 0.01) and 5.8 ± 1.4 pg/mg in 20 min; In control group, DynA1-13 concentration did not changed (Figure 3(c)).

4. Discussions

Serotonin is an important neurotransmitter to regulate the pain process in the spinal cord through 5-HT receptor. 5-HT1/2A/2C and 5-HT1/2C receptors increases the descending facilitation mechanisms induced by incision in the ipsilateral paw; 5-HT2A/3 receptors contribute to descending pronociceptive pathways conveyed by lamina X spinal neurons [19]. The descending serotonergic pathways and spinal 5-HT7 receptors play a crucial role in the antinociceptive effects [20].

Endogenous opiate peptide system is involved in the serotonin effecting pain modulation. Endogenous opiate peptide may partly act as a necessary mediator for the serotonin-induced suppression on the spinal transmission of nociceptive input [21,22]. Some studies have pointed that endogenous opiate peptide is involved in serotoninproduced antinociception at the spinal level using the tail-flick assay, which effect may be mediated through different types of opiate receptors [14]. Combination of serotonin and δ-selective opiates is more effective in suppressing noxiously evoked activity than combinations with μ-selective opiates [23]. The present study showed that 1) pain stimulation increased not only L-Ek, β-Ep, DynA1-13 concentrations but also serotonin and 5-HIAA concentrations in the spinal cord significantly; 2) serotonin increased L-Ek, β-Ep and DynA1-13 concentrations in the spinal cord in a dose-dependent manner; 3) cypotolamine, a serotonin receptor antagonist decreased L-Ek, β-Ep and DynA1-13 concentrations in the spinal cord. The data suggested that the antinociceptive role of serotonin at spinal level was relating with the endogenous opiate peptide system through serotonin receptors. Our previous study has shown that pain stimulation can influence the endogenous opiate peptide and serotonin system in the nucleus raphe magnus [24].

Chronic nerve injury evoked hypernociception may be contributed by genetic differences of descending serotonergic inhibitory control [25]. Opiates mediates their stimulatory effects on stimulate prolactin release, at least in part, through a serotonergic mechanism in adult rats [26]. Serotonin may influence the gene expression or peptide synthesis process to act the endogenous opiate peptide system in spinal cord. However, it needs to be studied in the near further.

In conclusion, the present study makes it clear that 1) the spinal cord releases endogenous opiate peptides and serotonin during pain process; 2) serotonin enhances, whereas the serotonin receptor antagonist inhibits the spinal cord release of endogenous opiate peptides. The data indicated that the antinociceptive role of serotonin at spinal level was relating with endogenous opiate peptide system via serotonin receptors.

5. Acknowledgements

This work was supported by Xinxiang Medical University, Subei People’s Hospital of Jiangsu Province and grants from National Natural Science Foundation of China (81100956/H0912).


  1. D. J. Walther, J. U. Peter, S. Bashammakh, H. Hörtnagl, M. Voits, H. Fink and M. Bader, “Synthesis of Serotonin by a Second Tryptophan Hydroxylase Isoform,” Science, Vol. 299, 2003, p. 76. doi:10.1126/science.1078197
  2. H. G. Lee, W. M. Kim, C. H. Park and M. H. Yoon, “Roles of Adenosine and Serotonin Receptors on the Antinociception of Sildenafil in the Spinal Cord of Rats,” Yonsei Medical Journal, Vol. 51, No. 6, 2010, pp. 960- 964. doi:10.3349/ymj.2010.51.6.960
  3. Z. Song, C. Ultenius, B. A. Meyerson and B. Linderoth, “Pain Relief by Spinal Cord Stimulation Involves Serotonergic Mechanisms: An Experimental Study in a Rat Model of Mononeuropathy,” Pain, Vol. 147, No. 1, 2009, pp. 241-248. doi:10.1016/j.pain.2009.09.020
  4. F.-Y. Liu, X.-X. Qu, X. Ding, J. Cai, H. Jiang, Y. Wan, J.-S. Han and G.-G. Xing, “Decrease in the Descending Inhibitory 5-HT System in Rats with Spinal Nerve Ligation,” Brain Research, Vol. 1330, 2010, pp. 45-60. doi:10.1016/j.brainres.2010.03.010
  5. J. Hughes, T. W. Smith, H. W. Kosterlitz, L. A. Fothergill, B. A. Morgan and H. R. Morris, “Identification of Two Related Pentapeptides from the Brain with Potent Opiate Agonist Activity,” Nature, Vol. 258, 1975, pp. 577-580. doi:10.1038/258577a0
  6. L. H. Lazarus, N. Ling and R. Guillemin, “β-Lipotropin as a Prohormone for the Morphinomimetic Peptides Endorphins and Enkephalins,” Proceedings of the National Academy of Sciences, Vol. 73, No. 6, 1976, pp. 2156-2159. doi:10.1073/pnas.73.6.2156
  7. A. Goldstenin, S. Tachibana, L. I. Lowney, M. Hunkapiller and L. Hood, “Dynorphin-(1-13), an Extraordinarily Potent Opioid Peptide,” Proceedings of the National Academy of Sciences of the USA, Vol. 76, No. 12, 1979, pp. 6666-6670. doi:10.1073/pnas.76.12.6666
  8. M. J. Millan and A. Herz, “The Endocrinology of the Opioids,” International Review of Neurobiology, Vol. 26, 1985, pp. 1-83. doi:10.1016/S0074-7742(08)60072-0
  9. R. J. Bodnar, “Endogenous Opiates and Behavior: 2009,” Peptides, Vol. 31, No. 12, 2010, pp. 2325-2359. doi:10.1016/j.peptides.2010.09.016
  10. A. Herz and M. J. Millan, “Opioids and Opioid Receptors Mediating Antinociception at Various Levels of the Neuraxis,” Physiol Bohemoslov, Vol. 39, No. 5, 1990, pp. 395-401.
  11. J. P. Rosenfeld, “Interacting Brain Stem Components of Opiate-Activated, Descending, Pain-Inhibitory Systems,” Neuroscience & Biobehavioral Reviews, Vol. 18, No. 3, 1994, pp. 403-409. doi:10.1016/0149-7634(94)90053-1
  12. J. A. Stamford, “Descending Control of Pain,” British Journal of Anaesthesia, Vol. 75, 1995, pp. 217-227.
  13. Z.-Q. Zhao, “Neural Mechanism Underlying Acupuncture Analgesia,” Progress in Neurobiology, Vol. 85, No. 4, 2008, pp. 355-375. doi:10.1016/j.pneurobio.2008.05.004
  14. S.-W. Yang, Z.-H. Zhang, R. Wang, Y.-F. Xie, J.-T. Qiao and N. Dafny, “Norepinephrine and Serotonin-Induced Antinociception Are Blocked by Naloxone with Different Dosages,” Brain Research Bulletin, Vol. 35, No. 2, 1994, pp. 113-117. doi:10.1016/0361-9230(94)90090-6
  15. T. Crisp, J. L. Stafinsky, J. E. Hess and M. Uram, “Spinal β-Endorphin Analgesia Involves an Interaction with Local Monoaminergic Systems,” European Journal of Pharmacology, Vol. 160, No. 2, 1989, pp. 211-217. doi:10.1016/0014-2999(89)90493-7
  16. M. O. Carruba, E. Nisoli, V. Garosi, P. Sacerdote, A. E. Panerai and M. da Prada, “Catecholamine and Serotonin Depletion from Rat Spinal Cord: Effects on Morphine and Footshock Induced Analgesia,” Pharmacological Research, Vol. 25, No. 2, 1992, pp. 187-194. doi:10.1016/1043-6618(92)91387-V
  17. G. González-Mariscal, P. Gómora and C. Beyer, “Participation of Opiatergic, GABAergic, and Serotonergic Systems in the Expression of Copulatory Analgesia in Male Rats,” Pharmacology Biochemistry and Behavior, Vol. 49, No. 2, 1994, pp. 303-307. doi:10.1016/0091-3057(94)90425-1
  18. M. Zimmermann, “Ethical Guidelines for Investigations of Experimental Pain in Conscious Animal,” Pain, Vol. 16, No. 2, 1983, pp. 109-110. doi:10.1016/0304-3959(83)90201-4
  19. J. W. Silveira, Q. M. Dias, E. A. Del Bel and W. A. Prado, “Serotonin Receptors Are Involved in the Spinal Mediation of Descending Facilitation of Surgical Incision-Induced Increase of Fos-Like Immunoreactivity in Rats,” Molecular Pain, Vol. 6, 2010, p. 17. doi:10.1186/1744-8069-6-17
  20. O. Yanarates, A. Dogrul, V. Yildirim, A. Sahin, A. Sizlan, M. Seyrek, O. Akgül, O. Kozak, E. Kurt and U. Aypar, “Spinal 5-HT7 Receptors Play an Important Role in the Antinociceptive and Antihyperalgesic Effects of Tramadol and Its Metabolite, O-Desmethyltramadol, via Activation of Descending Serotonergic Pathways,” Anesthesiology, Vol. 112, No. 3, 2010, pp. 696-710. doi:10.1097/ALN.0b013e3181cd7920
  21. Y.-J. Li, Z.-H. Zhang, J.-Y. Chen and J.-T. Qiao, “Effects of Intrathecal Naloxone and Atropine on the Nociceptive Suppression Induced by Norepinephrine and Serotonin at the Spinal Level in Rats,” Brain Research, Vol. 666, No. 1, 1994, pp. 113-116. doi:10.1016/0006-8993(94)90290-9
  22. A. H. Lichtman and M. S. Fanselow, “Opioid and Nonopioid Conditional Analgesia: The Role of Spinal Opioid, Noradrenergic, and Serotonergic Systems,” Behavioral Neuroscience, Vol. 105, No. 5, 1991, pp. 687-698. doi:10.1037/0735-7044.105.5.687
  23. K. Nakatani, L. M. Kitahata, Y. Harada, K. Omote, J. G. Collins and O. Yuge, “Interaction between Opiate Subtypes and Serotonin in Suppressing Noxiously Evoked Activity of WDR Neurons,” Nihon Masui Igakai, Vol. 44, No. 6, 1995, pp. 795-799.
  24. J. Yang, H. F. Yuan, J. G. Chu, Y. Yang, H. T. Xu, G. Wang, W. Y. Liu and B. C. Lin, “Arginine Vasopressin Antinociception in the Rat Nucleus Raphe Magnus Is Involved in the Endogenous Opiate Peptide and Serotonin System,” Peptides, Vol. 30, No. 7, 2009, pp. 1355-1361. doi:10.1016/j.peptides.2009.03.014
  25. N. Wijnvoord, B. Albuquerque, A. Häussler, T. Myrczek, L. Popp and I. Tegeder, “Inter-Strain Differences of Serotonergic Inhibitory Pain Control in Inbred Mice,” Molecular Pain, Vol. 6, 2010, p. 70. doi:10.1186/1744-8069-6-70
  26. L. A. Bero and C. M. Kuhn, “Role of Serotonin in Opiate-Induced Prolactin Secretion and Antinociception in the Developing Rat,” Journal of Pharmacology Exprimental Therapeutics, Vol. 240, No. 3, 1987, pp. 831-836.


*Corresponding author.

Journal Menu >>